Earnings Forecast Research on Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics, Inc. has received $-0.3 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.34 while the top line estimate is $-0.24 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -1106.67%.

Halozyme Therapeutics, Inc. reported better than expected with a surprise EPS of 14.81% or $0.04 during its most recent quarterly earnings. The Actual EPS was $-0.23 compared to the Estimated EPS of $-0.27.

In the last quarter, Halozyme Therapeutics, Inc. reported Annual Earnings of $-0.23. Based on the filings, last years Annual Earnings was, $-0.25. In the last Quarter, HALO reported a surprise Earnings per Share of 14.81% . The consensus estimate for current quarter is $-0.3 and for the current fiscal year, the estimate is $-0.9. For the Next fiscal year, the estimate is $-0.84 based on the consensus.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) : On Tuesday heightened volatility was witnessed in Halozyme Therapeutics, Inc. (NASDAQ:HALO) which led to swings in the share price. The stock opened for trading at $11.13 and hit $11.58 on the upside , eventually ending the session at $11.55, with a gain of 2.85% or 0.32 points. The heightened volatility saw the trading volume jump to 1,800,286 shares. The 52-week high of the share price is $14.38 and the company has a market cap of $1,496 million. The 52-week low of the share price is at $6.96 .

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The companys broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The companys initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozymes highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.


Share this post

Leave a Reply